已收盤 11-20 16:00:00 美东时间
-0.060
-2.17%
OnKure Therapeutics reported third-quarter 2026 financial results, highlighting advancements in its next-generation PI3Kα inhibitors OKI-345 for breast cancer and OKI-355 for vascular anomalies, with IND submissions planned for 1H 2027. The company also launched the PANORAMA registry to study vascular anomalies. Cash reserves stood at $163.3 million, with R&D expenses at $15.1 million and G&A at $4.3 million. The net loss was $17.8 million, or $0...
11-04 21:05
OnKure Therapeutics announced that its senior management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14-16, 2026. The company, focused on developing precision medicines for underserved vascular anomalies and cancers, will host one-on-one meetings with interested investors. For more information, visit www.onkure.com.
08-31 12:00
今日重点评级关注:富瑞:维持ProMIS Neurosciences"买入"评级,目标价从69美元升至100美元;Benchmark:维持Cineverse"买入"评级,目标价从12美元升至14美元
08-17 13:37
Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.
08-15 01:15
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $(0.54) by 158.49 percent. This is a 127.19 percent increase over losses of $(1.14) per share from the same period last year.
08-05 04:28
今日重点评级关注:Needham:维持Immuneering"买入"评级,目标价从11美元升至18美元;富瑞:维持塞德斯医疗"买入"评级,目标价从90美元升至100美元
07-21 11:36
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $27 to $21.
07-20 23:52
OnKure Therapeutics shares are trading lower after the company reported worse-t...
05-06 23:23
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.64) by 73.44 percent. This is a 6.72 percent increase over losses of $(1.19) per share
05-06 04:39
-- Financing led by Access Biotechnology with participation from new and existing investors-- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies –
03-27 20:12